Literature DB >> 10371334

A simple index using video image analysis to predict disease outcome in primary breast cancer.

C A Lockwood1, C Ricciardelli, W A Raymond, R Seshadri, K McCaul, D J Horsfall.   

Abstract

Image analysis was used to investigate the prognostic significance of immunostaining for oestrogen receptor (ER), p53 tumour-suppressor protein and tumour cell proliferation (MIB-1) in a random cohort of 200 primary breast cancer patients with between 4 and 7 years of clinical follow-up. Image measurements of the percentage of immunopositive cancer cell nuclei (% positive nuclear area) were recorded for the above tumour features for each patient. Assessment of relative risk using Cox's univariate analysis indicated that tumour size, number of cancer-involved nodes, MIB-1 and ER % positive nuclear area were significantly associated with breast cancer disease outcome, i.e., relapse-free survival and overall survival. In multivariate analysis, tumour size, number of involved nodes, ER and MIB-1 % positive nuclear area were retained as independent predictors of prognosis, depending on the image measurement cut-point used. A prognostic model, which can be used without reference to nodal involvement, was constructed for tumour size, ER cut-point of 30% positive nuclear area and MIB-1 cut-point of 10% positive nuclear area. Kaplan-Meier analysis of this image-based prognostic index identified 4 risk groups with predicted 5-year overall survival rates of 93%, 83%, 76.7% and 61.5%. We conclude that image measurements of ER and proliferative rate can be combined with tumour size to construct a prognostic index which reliably predicts disease outcome in primary breast cancer without knowledge of the nodal status of the patient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371334     DOI: 10.1002/(sici)1097-0215(19990621)84:3<203::aid-ijc1>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

2.  Estrogen receptor quantitative measures and breast cancer survival.

Authors:  Deirdre A Hill; Marc Barry; Charles Wiggins; Andrea Nibbe; Melanie Royce; Eric Prossnitz; Lesley Lomo
Journal:  Breast Cancer Res Treat       Date:  2017-08-19       Impact factor: 4.872

3.  Aromatase inhibitors and xenograft studies.

Authors:  Saranya Chumsri; Gauri J Sabnis; Timothy Howes; Angela M H Brodie
Journal:  Steroids       Date:  2011-03-21       Impact factor: 2.668

4.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

Review 5.  Aromatase, aromatase inhibitors, and breast cancer.

Authors:  Saranya Chumsri; Timothy Howes; Ting Bao; Gauri Sabnis; Angela Brodie
Journal:  J Steroid Biochem Mol Biol       Date:  2011-02-16       Impact factor: 4.292

Review 6.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

Review 7.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

8.  Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.

Authors:  Huiyan Ma; Yani Lu; Polly A Marchbanks; Suzanne G Folger; Brian L Strom; Jill A McDonald; Michael S Simon; Linda K Weiss; Kathleen E Malone; Ronald T Burkman; Jane Sullivan-Halley; Dennis M Deapen; Michael F Press; Leslie Bernstein
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

9.  The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.

Authors:  Esther J Campbell; Mathias Tesson; Flora Doogan; Zahra M A Mohammed; Elizabeth Mallon; Joanne Edwards
Journal:  Br J Cancer       Date:  2016-09-22       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.